<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) July 7, 1997
------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
- ----------------------------------------- -------- ---------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) File No.)
31 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ----------------------------------------- ---------------------------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
---------------
<PAGE>
Item 5. Other Events.
-------------
Boston Life Sciences, Inc. announced that Troponin I, the Company's anti-
angiogenic product in preclinical development, significantly inhibited the
growth of experimental primary human breast cancer in mice. The Company said
that in a recently-concluded experiment, where human breast cancer was implanted
into nude mice and recombinant Troponin I was then administered subcutaneously
over a 28 day period, tumor growth in the treated animals was significantly
inhibited compared to tumor growth in the control mice.
The Company indicated that the results of this study, together with previously
reported results showing inhibition of human prostate cancer growth in mice by
Troponin I, provide further important evidence of the potential therapeutic
efficacy of this naturally-derived anti-angiogenic protein for the treatment of
a variety of clinically important solid tumors. The Company has recently added
two senior members to its preclinical and regulatory affairs staff in order to
strengthen the development of Troponin I and other products in its pipeline.
BLSI is engaged in the research and development of novel treatments for cancer,
autoimmune diseases, and central nervous system disorders.
Item 7. Exhibits.
--------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated July 7, 1997.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: July 10, 1997 By:/s/ Joseph Hernon
-----------------
Joseph Hernon
Chief Financial Officer
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page
- ----------- ----
99.1 Press Release, dated July 7, 1997 5
<PAGE>
Exhibit 99.1
FOR IMMEDIATE RELEASE
BOSTON LIFE SCIENCES' ANTI-ANGIOGENIC FACTOR FOUND TO INHIBIT
HUMAN BREAST CANCER GROWTH IN MICE
BOSTON MA - JULY 7, 1997. BOSTON LIFE SCIENCES, INC. (NASDAQ: BLSI) announced
today that Troponin I, the Company's anti-angiogenic product in preclinical
development, significantly inhibited the growth of experimental primary human
breast cancer in mice. The Company said that in a recently-concluded
experiment, where human breast cancer was implanted into nude mice and
recombinant Troponin I was then administered subcutaneously over a 28 day
period, tumor growth in the treated animals was significantly inhibited compared
to tumor growth in the control mice.
"The results of this study, together with our previously reported results
showing inhibition of human prostate cancer growth in mice by Troponin, provide
further important evidence of the potential therapeutic efficacy of this
naturally-derived anti-angiogenic protein for the treatment of a variety of
clinically important solid tumors", stated Marc E. Lanser, MD, Chief Scientific
Officer of BLSI. "Our preclinical development program for Troponin I is
proceeding well. We have recently added two senior members to our preclinical
and regulatory affairs staff in order to strengthen our development of Troponin
and other products in our pipeline", added Dr. Lanser.
BLSI is engaged in the research and development of novel treatments for cancer,
autoimmune diseases, and central nervous system disorders. BLSI's products in
clinical trials or in pre-clinical development include Altropane for the
diagnosis of Parkinson's Disease; the above-mentioned anti-angiogenesis factor
for the treatment of solid tumors; Axogenesis Factor 1 (AF-1) for the treatment
of stroke and spinal cord injuries; THERAFECTIN/(R)/ for the treatment of
Rheumatoid Arthritis; and transcription factors to control the expression of
molecules associated with autoimmune disease and allergies.
For additional information contact:
Marc E. Lanser, MD
Chief Scientific Officer
617-425-0200
# # #
